🟢 BEAM is trading 4.1% up today extending a multi-day rebound on positive BEAM-302 trial data momentum

BEAM is trading at $35.28 (4.1% up), extending a strong multi-day rebound from last week’s pullback as momentum continues to build.

• Investors are continuing to react to recently reported promising Phase 1/2 BEAM-302 data for the treatment of alpha-1 antitrypsin deficiency.
• The move is supported by a generally risk-on sentiment across the biotech sector, despite no new company-specific catalysts emerging overnight.
• The stock is recovering significantly after facing downward pressure during the previous week's trading sessions.